Business Description
![Protagonist Therapeutics Inc Protagonist Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000B4TS.png?14)
Protagonist Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US74366E1029
Description
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 698.34 | |||||
Equity-to-Asset | 0.89 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 19.3 | |||||
Beneish M-Score | 339.22 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.3 | |||||
3-Year EBITDA Growth Rate | 3.8 | |||||
3-Year EPS without NRI Growth Rate | 10 | |||||
3-Year FCF Growth Rate | 16.2 | |||||
3-Year Book Growth Rate | -3 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 79.37 | |||||
9-Day RSI | 68.36 | |||||
14-Day RSI | 64.13 | |||||
6-1 Month Momentum % | 29.62 | |||||
12-1 Month Momentum % | 6.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 15.72 | |||||
Quick Ratio | 15.72 | |||||
Cash Ratio | 8.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.7 | |||||
Shareholder Yield % | -5.18 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 47.21 | |||||
Net Margin % | 51.47 | |||||
FCF Margin % | -20.37 | |||||
ROE % | 47.41 | |||||
ROA % | 43.17 | |||||
ROIC % | 223.46 | |||||
ROC (Joel Greenblatt) % | 5399.01 | |||||
ROCE % | 42.75 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 14.2 | |||||
Forward PE Ratio | 26.67 | |||||
PE Ratio without NRI | 14.2 | |||||
PEG Ratio | 11.83 | |||||
PS Ratio | 6.93 | |||||
PB Ratio | 3.62 | |||||
Price-to-Tangible-Book | 3.62 | |||||
EV-to-EBIT | 11.5 | |||||
EV-to-EBITDA | 11.25 | |||||
EV-to-Revenue | 5.43 | |||||
EV-to-Forward-Revenue | 6.71 | |||||
EV-to-FCF | -26.65 | |||||
Price-to-Graham-Number | 1.51 | |||||
Price-to-Net-Current-Asset-Value | 3.64 | |||||
Price-to-Net-Cash | 8 | |||||
Earnings Yield (Greenblatt) % | 8.7 | |||||
FCF Yield % | -3.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Protagonist Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 314.953 | ||
EPS (TTM) ($) | 2.44 | ||
Beta | 2.66 | ||
Volatility % | 65.09 | ||
14-Day RSI | 64.13 | ||
14-Day ATR ($) | 1.582183 | ||
20-Day SMA ($) | 32.7075 | ||
12-1 Month Momentum % | 6.73 | ||
52-Week Range ($) | 13.72 - 35.96 | ||
Shares Outstanding (Mil) | 58.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Protagonist Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Protagonist Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Protagonist Therapeutics Inc Frequently Asked Questions
What is Protagonist Therapeutics Inc(PTGX)'s stock price today?
The current price of PTGX is $34.65. The 52 week high of PTGX is $35.96 and 52 week low is $13.72.
When is next earnings date of Protagonist Therapeutics Inc(PTGX)?
The next earnings date of Protagonist Therapeutics Inc(PTGX) is 2024-08-02 Est..
Does Protagonist Therapeutics Inc(PTGX) pay dividends? If so, how much?
Protagonist Therapeutics Inc(PTGX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |